Florbetaben F-18 (Neuraceq®): A Comprehensive Monograph on a Key Diagnostic Agent for Amyloid Pathology

Section 1: Compound Profile and Chemical Characteristics

This section establishes the fundamental identity of Florbetaben F-18, serving as a foundational reference by detailing its nomenclature, classification, and key physicochemical properties. These characteristics are critical for understanding its biological behavior, mechanism of action, and application in positron emission tomography (PET).

1.1 Nomenclature and Identification

Florbetaben F-18 is a small molecule radiopharmaceutical recognized by a variety of names and identifiers across scientific, regulatory, and commercial domains. Its consistent identification is crucial for research, clinical practice, and regulatory oversight.

The internationally recognized generic name is Florbetaben (¹⁸F).[1] It is marketed exclusively under the brand name Neuraceq®.[3] In scientific literature and during its development phase, it was also referred to by the development codes BAY94-9172 and AV-1.[1]

From a chemical standpoint, its structure is precisely defined by the International Union of Pure and Applied Chemistry (IUPAC) systematic name: 4-[(E)-2-[2-[2-(2-($^{18}$F)fluoranylethoxy)ethoxy]ethoxy]phenyl]ethenyl]-N-methylaniline.[2] This name describes every component of the molecule, including the radioactive fluorine-18 isotope.

For database and regulatory tracking, Florbetaben F-18 is assigned several unique identifiers. The Chemical Abstracts Service (CAS) has assigned it the number 902143-01-5.[3] In the DrugBank database, it is cataloged under the accession number DB09148.[1] Other key identifiers include its Unique Ingredient Identifier (UNII) TLA7312TOI and its Chemical Entities of Biological Interest (ChEBI) ID, CHEBI:79033.[1] These identifiers ensure unambiguous reference to the specific active substance in global databases and regulatory filings.

1.2 Chemical Structure and Classification

Florbetaben F-18 possesses a distinct chemical structure that dictates its function as an amyloid-targeting PET tracer. Its molecular formula is C21​H2618​FNO3​, and it has a molecular weight of approximately 358.44 g·mol⁻¹.[2]

Structurally, Florbetaben F-18 is classified as a fluorine-18 (¹⁸F)-labeled stilbene derivative.[1] The core of the molecule is a

trans-stilbene backbone, a hydrocarbon consisting of two phenyl groups linked by an ethene double bond. This core is modified with specific functional groups that impart its desired biological properties. It is a member of the stilbenoid class, where the para-hydrogens of the stilbene are replaced by a methylamino group on one phenyl ring and a 2-{2-[2-((¹⁸F)fluoroethoxy]ethoxy}ethoxy) group on the other.[1] This complex side chain, a type of polyether, enhances the molecule's pharmacokinetic properties. The presence of these groups also means the molecule can be further classified as a substituted aniline, a secondary amino compound, and an aromatic ether.[1]

The most critical feature of the molecule is the incorporation of the positron-emitting radionuclide, fluorine-18 (¹⁸F), which classifies it as an ¹⁸F radiopharmaceutical.[1] The ¹⁸F isotope has a physical half-life of approximately 110 minutes (109.8 minutes) and decays to stable oxygen-18 (¹⁸O).[4] This decay process occurs through positron (β+) emission, with a maximum positron energy of 634 keV. The emitted positron travels a very short distance in tissue before it encounters an electron, leading to an annihilation event. This event produces a pair of high-energy (511 keV) gamma photons that travel in nearly opposite directions (180° apart). The coincident detection of these photon pairs by a PET scanner is the fundamental principle that allows for the three-dimensional mapping of the tracer's location within the body.[4] The half-life of ¹⁸F is considered ideal for clinical PET imaging, as it is long enough to allow for complex radiosynthesis, quality control, and distribution to imaging centers, yet short enough to minimize the patient's radiation exposure.[8]

Table 1: Chemical and Physical Properties of Florbetaben F-18

Property	Value	Source(s)
DrugBank ID	DB09148	1
CAS Number	902143-01-5	3
UNII	TLA7312TOI	1
Molecular Formula	C21​H2618​FNO3​	2
Molecular Weight	358.44 g·mol⁻¹	3
IUPAC Name	4-[(E)-2-[2-[2-(2-($^{18}$F)fluoranylethoxy)ethoxy]ethoxy]phenyl]ethenyl]-N-methylaniline	2
InChI	InChI=1S/C21H26FNO3/c1-23-20-8-4-18(5-9-20)2-3-19-6-10-21(11-7-19)26-17-16-25-15-14-24-13-12-22/h2-11,23H,12-17H2,1H3/b3-2+/i22-1	2
InChIKey	NCWZOASIUQVOFA-FWZJPQCDSA-N	2
SMILES	CNC1=CC=C(C=C1)/C=C/C2=CC=C(C=C2)OCCOCCOCC[$^{18}$F]	2

---

Section 2: Molecular Mechanism of Action and In Vivo Pharmacodynamics

The clinical utility of Florbetaben F-18 is rooted in its precise molecular mechanism of action and its resulting pharmacodynamic behavior within the central nervous system. This section details how the tracer functions at a molecular and physiological level to enable the visualization of amyloid plaques, analyzing the specificity and clinical implications of its binding characteristics.

2.1 Principle of Action as a PET Radiopharmaceutical

Florbetaben F-18 is classified as a Radioactive Diagnostic Agent, and its mechanism is defined as Positron Emitting Activity.[1] The process begins with intravenous administration, after which the molecule must overcome a significant physiological hurdle: the blood-brain barrier (BBB).[1] Its chemical structure, particularly its lipophilicity derived from the stilbene backbone, facilitates this transit, allowing it to enter the brain parenchyma.

Once inside the brain, Florbetaben F-18 demonstrates its primary function by binding with high affinity to β-amyloid neuritic plaques.[6] These plaques are extracellular aggregates of the amyloid-beta (Aβ) peptide, arranged in a characteristic fibrillar β-sheet conformation, and are a core neuropathological hallmark of Alzheimer's disease (AD).[3] The binding of Florbetaben F-18 to these structures is the key event that allows for their detection.

The attached ¹⁸F radioisotope serves as the signaling beacon. Through positron emission and subsequent annihilation, it generates the paired 511 keV gamma photons that are detected by the PET scanner.[9] The scanner's detectors register these coincident photon events, and sophisticated reconstruction algorithms use this information to create a three-dimensional map of the tracer's distribution. In regions with high concentrations of β-amyloid plaques, more tracer is bound and retained, resulting in a higher signal intensity on the final PET image. Conversely, regions with little to no plaque burden show lower signal intensity.[10]

2.2 Binding Affinity and Specificity

The diagnostic reliability of Florbetaben F-18 hinges on its high affinity and, critically, its high specificity for its target. In vitro binding experiments have quantified its affinity for β-amyloid. Studies using radiolabeled (tritiated) florbetaben on homogenates of frontal cortex tissue from deceased AD patients have revealed a complex binding profile with two distinct binding sites, characterized by dissociation constants (Kd​) of 16 nM and 135 nM.[6] The presence of two

Kd​ values, rather than a single one, suggests a multifaceted interaction with the target. This may reflect the known structural heterogeneity of amyloid plaques; the higher affinity site (16 nM) could represent binding to the dense, fibrillar core of the plaque, while the lower affinity site (135 nM) might correspond to interactions with less organized or peripheral amyloid aggregates. This nuanced binding could influence the tracer's ability to detect amyloid across different stages of plaque development. Further confirmation of its potent binding comes from its interaction with the Amyloid beta A4 protein (the precursor to the Aβ peptide), for which a binding affinity constant (Ki​) of 8.65 (-log[M]) has been reported.[9]

Of paramount importance is the tracer's specificity. For an amyloid imaging agent to be clinically useful, it must not bind significantly to other protein aggregates that co-exist in the brains of patients with neurodegenerative diseases. Extensive in vitro studies have validated this crucial property. Autoradiography on post-mortem brain sections has shown that Florbetaben F-18 binding correlates well with traditional silver staining and immunohistochemical methods for detecting β-amyloid plaques.[6] These same studies have demonstrated that Florbetaben F-18 does not bind to neurofibrillary tangles composed of hyperphosphorylated tau protein, another key hallmark of AD.[3] Furthermore, it shows no significant binding to α-synuclein aggregates (found in Parkinson's disease and dementia with Lewy bodies) or to the specific forms of tau found in frontotemporal dementia.[3] This high degree of selectivity ensures that the signal detected on a PET scan is a true representation of the brain's β-amyloid plaque burden. This specificity is what allows Florbetaben F-18 to serve as a precise biomarker for the "A" (Amyloid) component within the modern "A/T/N" (Amyloid/Tau/Neurodegeneration) biological framework for defining and staging Alzheimer's disease.[12] It enables clinicians and researchers to assess one key pathology in isolation, providing clear and unambiguous information for diagnosis and trial enrollment.

2.3 Pharmacodynamic Effect and Basis for Image Interpretation

The ultimate pharmacodynamic effect of Florbetaben F-18 is the creation of a detectable contrast within the brain based on the presence or absence of its target. Following its entry into the brain, the tracer's fate is dictated by the local molecular environment. In a brain with sparse or no amyloid plaques, the tracer does not bind specifically and is gradually cleared from the tissue, a process known as "washout," driven by normal cerebral perfusion.[1] In contrast, in a brain with a significant plaque burden, the tracer binds to and is retained on these plaques for a prolonged period.[1]

This differential retention is the cornerstone of the image interpretation methodology.[11] PET images are acquired during a time window when the tracer has had sufficient time to bind to plaques but has largely washed out from normal brain tissue and the surrounding blood pool. The interpretation relies on comparing the signal intensity in cortical gray matter, where amyloid plaques preferentially accumulate, to the signal intensity in adjacent white matter.[1] White matter typically has a low level of non-specific tracer uptake and serves as an effective internal reference.

In a negative scan (no significant amyloid), the gray matter signal is lower than the white matter signal, preserving a clear visual contrast between the two tissue types.[11] In a positive scan (moderate to frequent amyloid), the tracer retention in the gray matter causes its signal to become equal to or greater than that of the white matter, leading to a reduction or complete loss of this gray-white contrast.[11] This visually apparent change forms the basis for the binary diagnostic readout (amyloid-positive or amyloid-negative).

---

Section 3: Comprehensive Pharmacological Profile: Pharmacokinetics (ADME)

A thorough understanding of the absorption, distribution, metabolism, and excretion (ADME) of Florbetaben F-18 is essential for rationalizing its clinical use. The pharmacokinetic profile dictates the recommended dosage, the method of administration, and, most critically, the optimal timing for PET image acquisition to ensure a high-quality, diagnostically accurate scan.

3.1 Absorption and Distribution

As a diagnostic agent administered intravenously, traditional oral absorption metrics are not applicable. The drug is introduced directly into the systemic circulation as a single, slow intravenous bolus, typically at a rate of 6 sec/mL.[6]

Following injection, Florbetaben F-18 is rapidly distributed throughout the body. This is evidenced by the swift decline in plasma concentrations of ¹⁸F radioactivity. Measurements in human volunteers show that plasma levels drop by approximately 75% within 20 minutes and by 90% within 50 minutes post-injection.[14] This rapid clearance from the blood is due to extensive uptake into various body tissues. A significant factor influencing its distribution is its high affinity for plasma proteins, with studies showing that 98.5% of the tracer is protein-bound in circulation.[14] While high protein binding can sometimes limit the availability of a drug to cross the BBB, the lipophilic nature of Florbetaben F-18 ensures that the small unbound fraction is still able to efficiently enter the central nervous system.

The uptake of the tracer into the brain is both rapid and significant. Peak brain radioactivity, representing approximately 6% of the total injected dose, is achieved within 10 minutes of injection.[18] This rapid CNS penetration is a key feature, allowing the tracer to reach its target quickly and begin the binding process that is central to its mechanism.

3.2 Metabolism

Florbetaben F-18 undergoes rapid and extensive metabolism in the body. This metabolic process is crucial for its function, as it helps to clear the tracer from the blood and generates metabolites that do not interfere with brain imaging. By 60 minutes after injection, only about 6% of the radioactivity remaining in the plasma is attributable to the unchanged parent Florbetaben F-18 molecule; the vast majority has been converted into various metabolites.[19]

In vitro studies have identified the primary enzymatic pathways responsible for this metabolism. The process is predominantly catalyzed by the cytochrome P450 (CYP) enzyme system in the liver. Specifically, CYP2J2 and CYP4F2 have been identified as the main contributors.[1] Further investigation has shown that the CYP4F2 enzyme is primarily responsible for the N-demethylation of the molecule (removing the methyl group from the amine), while CYP2J2 and, to a lesser extent, CYP3A4, are involved in forming more polar metabolites.[18]

The resulting metabolites are predominantly polar compounds.[8] This polarity is a critical feature of the tracer's design. Polar molecules are generally unable to cross the lipophilic blood-brain barrier. Therefore, even though these metabolites are radiolabeled, they remain in the systemic circulation and do not enter the brain to create a confounding background signal. This ensures that the signal detected by the PET scanner from within the brain is almost exclusively from the parent Florbetaben F-18 compound bound to amyloid plaques, thereby maximizing the signal-to-noise ratio and image clarity.

3.3 Excretion

The body eliminates Florbetaben F-18 and its metabolites primarily through the hepatobiliary system, with subsequent renal excretion of the water-soluble metabolites.[18] Whole-body imaging studies confirm this pathway, showing an initial accumulation of radioactivity in the liver shortly after injection, followed by clearance into the biliary tract and gastrointestinal system.[13]

A significant portion of the metabolites is ultimately excreted in the urine. Up to 30% of the initial injected dose of radioactivity (corrected for physical decay) can be recovered in the urine within 12 hours of administration.[19] Analysis of the urine confirms that virtually all of this excreted radioactivity is in the form of the polar metabolites. Only trace amounts of the unchanged parent drug are found, underscoring the efficiency of the body's metabolic processes.[1]

The overall clearance of the parent drug from the plasma is relatively fast, with a mean biological half-life of approximately 1 hour.[18] This pharmacokinetic profile is well-suited for its diagnostic purpose: rapid delivery to the brain, followed by efficient clearance from the blood and metabolism into non-brain-penetrant forms, creating an optimal and stable imaging window.

3.4 Influence of Special Populations and Factors

To ensure broad applicability, the pharmacokinetics of Florbetaben F-18 have been evaluated in different populations.

• Ethnicity: Dedicated Phase I clinical trials were conducted to compare the pharmacokinetics between German (Caucasian) and Japanese healthy volunteers. These studies found no clinically significant differences in the plasma concentration profiles, the rate of metabolism, the types of metabolites formed, or the patterns of urinary excretion between the two ethnic groups.[8] This finding was important for justifying the use of Florbetaben F-18 in global clinical trials and for its marketing in diverse populations.
• Mass Dose: The amount of non-radioactive florbetaben administered along with the tracer (the "mass dose") can vary depending on the specific activity of the production batch. Studies were performed to assess whether this variation (up to 55 µg) would affect the tracer's behavior. The results showed that the effect of mass dose on the overall pharmacokinetics was minimal, indicating that the tracer's binding is not saturated at these levels and that its performance is consistent across the expected range of specific activities.[8]
• Renal Impairment: The influence of kidney function on the tracer has also been studied. In patients with mild to moderate renal impairment, no impact on the efficacy of Florbetaben F-18 was observed, and consequently, no dose adjustment is recommended for this population.[19] The effects of severe renal impairment or hepatic impairment have not been formally characterized.

Table 2: Summary of Key Pharmacokinetic Parameters for Florbetaben F-18

Parameter	Value / Description	Source(s)
Route of Administration	Intravenous (slow bolus)	17
Time to Max. Brain Uptake	~10 minutes post-injection	18
% Injected Dose in Brain	~6% at maximum uptake	19
Plasma Half-Life	~1 hour	18
Plasma Protein Binding	98.5%	14
Primary Metabolic Enzymes	CYP2J2, CYP4F2	1
Primary Route of Elimination	Hepatobiliary	18
Primary Route of Excretion	Renal (as polar metabolites)	19

---

Section 4: Clinical Efficacy and Validation in Pivotal Trials

The clinical acceptance and regulatory approval of any diagnostic agent depend on robust evidence of its efficacy. This section provides a detailed analysis of the pivotal clinical trial data that established the diagnostic performance of Florbetaben F-18. The cornerstone of this evidence is the Phase 3 study that directly compared in-vivo PET imaging with the definitive gold standard of post-mortem neuropathological examination.

4.1 Pivotal Phase 3 Trial Design

The pivotal study for Florbetaben F-18 was a multicenter, open-label, non-randomized trial with a methodologically rigorous design.[22] The study enrolled end-of-life individuals with a range of cognitive statuses who had consented to brain autopsy upon their death. This design is critical because it allows for a direct, one-to-one comparison between the image taken during life (the in-vivo PET scan) and the actual state of the brain tissue after death (the post-mortem histopathology).[23] This approach provides the highest possible level of evidence for a diagnostic imaging agent, as it validates the scan against the "ground truth" of the underlying pathology, rather than against a less certain clinical diagnosis. The primary objective was to determine the sensitivity and specificity of the visual assessment of Neuraceq PET scans for detecting moderate to frequent neuritic amyloid plaques, as confirmed by histology.[24]

4.2 Efficacy Results: Correlation with Neuropathology

The results of the pivotal trial demonstrated a strong and statistically significant correlation between the signal on the Florbetaben F-18 PET scan and the density of β-amyloid plaques confirmed by neuropathology.[3] This validation confirmed that the tracer was indeed imaging its intended target with high accuracy.

The study's primary endpoints of sensitivity and specificity were evaluated in a cohort of 82 subjects who had undergone both PET imaging and subsequent autopsy. The PET scans were interpreted by multiple trained readers who were blinded to all clinical and pathological information. When the visual scan readings were compared against the most rigorous histopathological standard (a combination of Bielschowsky silver stain and immunohistochemistry for Aβ), the diagnostic performance was excellent. For a group of expert readers who received in-person training, the median sensitivity was 98.2%, and the median specificity was 92.3%.[23] This means the scan correctly identified nearly all patients who had significant amyloid pathology and correctly ruled it out in the vast majority of those who did not.

These high sensitivity and specificity values translate into strong predictive power in a clinical context. The negative predictive value (NPV) was reported to be 96.0%, and the positive predictive value (PPV) was 93.9%.[3] The high NPV is particularly valuable clinically, as it means a negative Neuraceq scan provides a high degree of confidence that a patient's cognitive impairment is not due to Alzheimer's disease pathology, allowing clinicians to more confidently explore other potential causes.

4.3 Reader Agreement and Robustness

For a diagnostic imaging test to be widely adopted, its interpretation must be consistent and reproducible across different clinicians. The pivotal trial therefore extensively evaluated the robustness of the visual assessment method. The study assessed inter-reader agreement (the consistency of reads among different readers) and intra-reader agreement (the consistency of reads by the same reader at different times).

The results showed a high degree of concordance. For the expert, in-person trained readers, the inter-reader agreement was excellent, with a Fleiss' kappa (κ) statistic of 0.89.[23] A kappa value approaching 1.0 indicates near-perfect agreement. The intra-reader agreement was also very high, with a median kappa of 0.90.[23]

Crucially, the study also evaluated a group of readers who had no prior experience with amyloid PET imaging and who received training via a remote, electronic program. Even in this group, the performance remained strong. The median sensitivity was 96.4% and specificity was 88.5%.[23] The inter-reader agreement was "very good" (κ = 0.71), and the intra-reader agreement was also high (median κ = 0.90).[23] This finding is of great practical importance. It demonstrates that the visual features of a positive or negative Neuraceq scan are distinct and can be taught effectively through a standardized training program. This ensures that the diagnostic method is scalable and can be reliably deployed in diverse clinical settings beyond a few specialized academic centers, facilitating its broad integration into routine neurological practice.

4.4 Clinical Utility in Target Populations

Beyond the pivotal autopsy study, other clinical investigations have demonstrated the utility of Florbetaben F-18 in its intended patient populations. Studies have consistently shown that, as a group, patients with a clinical diagnosis of Alzheimer's disease or Mild Cognitive Impairment (MCI) exhibit significantly higher cortical tracer uptake compared to age-matched healthy control subjects.[3]

Furthermore, longitudinal studies have provided evidence for its prognostic value. In cohorts of patients with MCI, a positive Florbetaben F-18 scan at baseline has been shown to be associated with a significantly higher likelihood of progressing to a clinical diagnosis of AD dementia over subsequent years.[3] This indicates that the presence of amyloid pathology, as detected by the scan, is a key indicator of future clinical decline. The importance of Florbetaben F-18 as a validated biomarker is further underscored by its inclusion in major observational research studies, such as the Alzheimer's Disease Neuroimaging Initiative (ADNI).[26] Its use in ADNI3 helps researchers to better understand the natural history of AD, correlate biomarker changes with clinical outcomes, and validate new potential therapies.

Table 3: Efficacy Results from the Pivotal Phase 3 Autopsy-Correlated Trial

Reader Group	Standard of Truth	Median Sensitivity	Median Specificity	Median Accuracy
In-Person-Trained	BSS + IHC	98.2%	92.3%	95.1%
E-Trained	BSS + IHC	96.4%	88.5%	91.5%
In-Person-Trained	BSS only	98.1%	80.0%	91.5%
E-Trained	BSS only	96.2%	76.7%	86.6%
Reader Agreement	Metric	In-Person-Trained	E-Trained
Inter-Reader Agreement	Fleiss' κ	0.89 (Excellent)	0.71 (Very Good)
Intra-Reader Agreement	Median κ	0.90	0.90
Data sourced from.23 BSS = Bielschowsky Silver Stain; IHC = Immunohistochemistry.

---

Section 5: Regulatory and Development History

The development and approval of Florbetaben F-18 represent a significant milestone in the field of dementia diagnostics. This section provides a chronological overview of its regulatory journey with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), and details its evolving role in clinical practice.

5.1 Initial Approvals and Indications

Following the successful completion of pivotal clinical trials, the manufacturer, then Piramal Imaging, sought marketing authorization from major global regulatory bodies.

• European Medicines Agency (EMA): The EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for Neuraceq in December 2013.[28] This led to the formal granting of marketing authorization by the European Commission on February 20, 2014, making the product available for use throughout the European Union.[1]
• U.S. Food and Drug Administration (FDA): In the United States, Neuraceq received FDA approval shortly thereafter, on March 19, 2014.[9]

The initial indication granted by both the FDA and EMA was for the use of Neuraceq with Positron Emission Tomography (PET) imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer's Disease (AD) and other causes of cognitive decline.[1] This indication positioned Neuraceq as a key diagnostic tool to be used as an adjunct to a comprehensive clinical evaluation, helping to increase or decrease the certainty of an AD diagnosis.

5.2 Expanded Indications and Post-Approval Developments

The clinical landscape for Alzheimer's disease has evolved dramatically since 2014 with the development of amyloid-targeting therapies. This evolution has directly impacted the role and regulatory status of amyloid PET imaging.

• FDA Indication Expansion: In June 2025, the FDA officially expanded the indications for Neuraceq.[30] The updated label now includes its use for the selection of patients who are candidates for amyloid beta-directed therapies.[15] This was a landmark regulatory action that transformed amyloid PET imaging from a purely diagnostic modality into a critical companion diagnostic. Before a patient can be considered for a therapy designed to remove amyloid plaques, their presence must first be confirmed. The expanded indication formally recognizes the essential role of agents like Neuraceq in this treatment paradigm, directly linking the diagnostic test to a therapeutic decision. This shift fundamentally increases the clinical importance of the scan, moving it from a tool that informs prognosis to one that determines eligibility for a disease-modifying treatment.
• Orphan Drug Designation for New Indications: Recognizing the broader potential of an amyloid-binding molecule, the manufacturer has pursued development for other diseases characterized by amyloid deposition. Florbetaben F-18 has been granted Orphan Drug Designation by both the EMA (June 2025) and the FDA for the diagnosis of systemic amyloidosis, specifically Transthyretin (ATTR) Amyloidosis and Amyloid Light-chain (AL) Amyloidosis.[1] These are rare diseases where amyloid proteins deposit in organs like the heart, causing severe organ dysfunction. This designation provides regulatory and financial incentives to develop the tracer for these underserved patient populations and represents a strategic expansion of the asset's value, leveraging its fundamental mechanism of action to address an unmet medical need in a completely different clinical specialty (cardiology).

5.3 Manufacturer and Commercialization

Neuraceq was developed and brought to market by Piramal Imaging SA.[31] The company is now known as Life Molecular Imaging GmbH, which continues to manufacture and commercialize the product globally.[1]

---

Section 6: Guidelines for Clinical Administration and PET Image Acquisition

The acquisition of a high-quality, diagnostically reliable Neuraceq PET scan is dependent on strict adherence to a standardized protocol. This section provides a practical, step-by-step guide for clinicians and nuclear medicine technologists on patient preparation, tracer administration, and PET image acquisition.

6.1 Patient Preparation

Preparation for a Neuraceq scan is straightforward and minimally burdensome for the patient.

• Dietary and Medication Restrictions: There are no specific requirements for fasting or for monitoring blood glucose levels prior to the scan.[35] Patients can typically maintain their normal diet and medication schedule.
• Hydration: A key preparatory step is to ensure the patient is well-hydrated. Patients should be instructed to drink water before the administration of Neuraceq and to continue hydrating after the procedure.[17] Adequate hydration helps to facilitate the clearance of the radiotracer and its metabolites from the body via the kidneys.
• Voiding: To minimize radiation exposure to the walls of the bladder, patients should be instructed to empty their bladder immediately before the PET scan begins and to void frequently in the hours following the procedure.[17]

6.2 Recommended Dosage and Administration

The administration of Neuraceq is a precise procedure that requires careful handling of the radioactive material.

• Dosage: The recommended amount of radioactivity for a single adult dose is 300 megabecquerels (MBq), which is equivalent to 8.1 millicuries (mCi). This dose is administered in a total volume of up to 10 mL. It is also specified that the maximum mass dose of the non-radioactive florbetaben compound should not exceed 30 micrograms.[6]
• Administration Technique:

1. Safety Precautions: Standard aseptic technique and appropriate radiation safety measures must be employed. This includes the use of waterproof gloves and effective radiation shielding, such as lead-glass syringe shields, during the withdrawal and injection of the tracer.[17]
2. Visual Inspection: Before administration, the solution in the vial must be visually inspected for any particulate matter or discoloration. The solution should be clear and colorless. If any particles or discoloration are present, the dose must not be used.[17]
3. Dose Calibration: The activity of the dose must be measured and confirmed in a dose calibrator immediately prior to injection.[17]
4. Injection: The dose should be administered as a single, slow intravenous bolus. The recommended injection rate is 6 seconds per milliliter.[17] It is preferable to use a large vein in the arm and a short IV catheter (e.g., 1.5 inches or less) to minimize the potential for the drug to adhere to the catheter material.[35] The solution should not be diluted.[17]
5. Flush: Immediately following the injection of Neuraceq, an intravenous flush of approximately 10 mL of 0.9% sodium chloride solution should be administered through the same catheter. This ensures that the full dose is delivered from the syringe and catheter into the patient's circulation.[17]

6.3 PET Image Acquisition Protocol

The timing and technical parameters of the PET scan are critical for obtaining optimal images.

• Patient Positioning: The patient must be positioned supine on the scanner bed. The head should be carefully positioned to center the entire brain, including the cerebellum, within the PET scanner's field of view. To minimize image degradation from patient movement during the scan, flexible head restraints, such as straps or tape, may be used.[17]
• Scan Timing (Uptake Period): The PET scan should begin between 45 and 130 minutes after the intravenous injection of Neuraceq.[17] This wide imaging window is a significant practical advantage. It allows for substantial flexibility in patient scheduling and can accommodate unforeseen delays in a busy clinical environment without compromising the quality of the scan. This logistical benefit distinguishes it from some other tracers that may have narrower or more restrictive uptake periods.[35]
• Scan Duration: The total emission scan duration should be 15 to 20 minutes.[17] This can be acquired as a single static image over the full duration or as a series of shorter dynamic frames (e.g., four 5-minute frames) which are then summed together during image processing.[36]
• Image Reconstruction: The raw PET data must be reconstructed using algorithms that include correction for photon attenuation. The resulting reconstructed images should have transaxial pixel sizes in the range of 2 to 3 mm to ensure adequate spatial resolution for interpretation.[17]

---

Section 7: Principles of Neuraceq® Image Interpretation

The diagnostic value of a Neuraceq PET scan is realized through its accurate and standardized interpretation. This process is not merely a subjective assessment but a structured visual analysis based on specific criteria. This section outlines the principles and methodology for interpreting Neuraceq images.

7.1 Prerequisite Reader Training

A fundamental requirement for interpreting Neuraceq images is the successful completion of a specialized training program provided by the manufacturer, Life Molecular Imaging.[17] This mandatory training ensures that all readers, regardless of their prior experience, are calibrated to the same specific visual criteria for what constitutes a positive or negative scan. This standardization is essential for maintaining high levels of diagnostic accuracy and inter-reader reliability, as was validated in the pivotal clinical trials.[23]

7.2 Image Display and Systematic Review

Proper image display and a systematic review process are crucial for a thorough and accurate interpretation.

• Image Display: The PET images should be displayed in the transaxial orientation, which provides the clearest view of the cortical gray-white matter junction. A gray scale or inverse gray scale is recommended for optimal visualization of contrast.[17] The coronal and sagittal planes may be used as supplementary views to aid in anatomical orientation and confirm findings from the transaxial slices.
• Systematic Review: Readers should adopt a consistent, systematic approach to reviewing the image set. A common and effective method is to start at the base of the brain to identify the cerebellum (which serves as a reference for normal gray-white contrast) and then scroll superiorly through the brain, carefully examining the four key cortical regions in order: the lateral temporal lobes, the frontal lobes, the posterior cingulate cortex/precuneus, and the parietal lobes.[11]
• Anatomical Co-registration: In certain cases, interpretation can be challenging. Severe brain atrophy, which is common in the elderly population being evaluated, can lead to a thinning of the cortical gray matter. Due to the inherent spatial resolution limits of PET, this can cause a "partial volume effect," where the signal from the thin cortex is averaged with the surrounding cerebrospinal fluid, potentially leading to an artificially low signal that could be misinterpreted as a negative scan. To mitigate this risk, it is highly recommended to use co-registered anatomical images (CT or MRI).[4] These high-resolution images allow the reader to precisely localize the gray matter and interpret the PET signal in its correct anatomical context, significantly improving accuracy in challenging cases.[17]

7.3 Visual Assessment Criteria

The core of the interpretation is a qualitative assessment of the brain's visual texture, based on the relative signal intensity between cortical gray matter and the adjacent white matter.[15]

• Negative Scan: A scan is interpreted as negative for amyloid plaques if there is a clear distinction between gray and white matter across all four key cortical regions. The signal intensity in the gray matter is visibly lower than that in the white matter. This high contrast creates a characteristic appearance where the gyri of the white matter look "spiculated" or like "mountain ranges," and the radioactive signal does not extend to the outer edge of the brain.[11] A negative scan indicates sparse to no neuritic plaques and significantly reduces the likelihood that the patient's cognitive impairment is due to Alzheimer's disease.[4]
• Positive Scan: A scan is interpreted as positive if the gray-white matter contrast is reduced or lost in at least one of the four cortical regions. This occurs when the signal intensity in the gray matter becomes equal to or higher than that of the adjacent white matter. This "filling in" of the cortical ribbon with signal results in a loss of the spiculated white matter appearance and creates a "plumped" or "smooth" contour at the outer edge of the brain parenchyma.[11] A positive scan is indicative of moderate to frequent amyloid neuritic plaques. It is a critical finding that confirms the presence of a core AD pathology. However, it is important to note that a positive scan does not, in isolation, diagnose AD, as amyloid plaques can also be found in older individuals with normal cognition and in other neurological conditions.[7] The scan result must always be integrated with the patient's overall clinical picture.

7.4 Role of Quantitative Analysis

While the primary, regulatory-approved method for clinical interpretation is visual assessment, quantitative analysis is increasingly being used as a valuable adjunct tool. FDA-authorized software packages are available that can automatically measure the tracer uptake in various brain regions and calculate metrics such as the Standardized Uptake Value Ratio (SUVR).[17] In this method, the average tracer uptake in a composite cortical target region is divided by the uptake in a reference region (like the cerebellum) to yield a continuous numerical value of amyloid burden.

Quantitative analysis offers several benefits. It can corroborate the findings of a visual read, increasing diagnostic confidence, particularly in borderline or ambiguous cases.[38] It provides an objective, reproducible measure that is less subject to inter-reader variability. In the context of clinical trials, quantification is essential for tracking longitudinal changes in amyloid burden and for assessing the target engagement of amyloid-lowering therapies.[39] As the field moves towards more data-driven diagnostics, the integration of quantitative analysis with visual assessment is likely to become the standard of care.

---

Section 8: Safety, Tolerability, and Radiation Dosimetry

The safety profile of a diagnostic agent is a paramount consideration, particularly for a tool used in an often elderly and vulnerable patient population. This section provides a comprehensive overview of the clinical safety, tolerability, and detailed radiation dosimetry of Florbetaben F-18.

8.1 Clinical Safety and Tolerability

Extensive clinical trial data have established that Florbetaben F-18 is a very well-tolerated agent. The overall safety profile is based on data from 872 subjects who received a total of 1,090 administrations of Neuraceq.[3]

• Adverse Reactions: Across this large dataset, no serious adverse reactions have been reported that were considered related to the administration of the tracer.[3] The vast majority of reported adverse events were mild to moderate in severity and transient in nature.
• Most Common Side Effects: The most frequently observed adverse reactions were localized to the injection site. These include injection site pain (reported in 3.4% to 3.9% of patients), injection site erythema (redness, 1.7%), and injection site irritation (1.1% to 1.2%).[3] These reactions are common with intravenous injections and typically resolve on their own without intervention.
• Other Potential Side Effects: As with any intravenously administered agent, there is a theoretical risk of hypersensitivity or allergic-type reactions. While the incidence is not known, potential symptoms could include hives, rash, itching, or more severe systemic reactions like chest tightness or difficulty breathing.[41] However, such events have not been a prominent feature in the clinical trial experience.

8.2 Contraindications, Warnings, and Precautions

The prescribing information for Neuraceq outlines specific warnings and precautions for its use.

• Contraindications: There are no known contraindications to the use of Neuraceq.[32]
• Warnings:
• Risk for Image Misinterpretation: The label contains a specific warning about the potential for errors in the interpretation of Neuraceq images. It emphasizes that image interpretation should be performed independently of the patient's clinical information to avoid bias. Factors such as severe brain atrophy or patient motion during the scan can create artifacts or limit the ability to clearly distinguish gray and white matter, potentially leading to an incorrect read.[16]
• Radiation Risk: As a radiopharmaceutical, Neuraceq administration results in patient exposure to ionizing radiation. The label includes a warning that this contributes to the patient's overall long-term cumulative radiation exposure, which is associated with an increased risk of cancer.[16] This is a class warning for all radiopharmaceuticals. It underscores the importance of ensuring that the procedure is medically indicated and that all necessary safety precautions are taken to minimize radiation exposure to both the patient and the healthcare providers handling the agent.[15]
• Use in Specific Populations:
• Pregnancy and Lactation: Radiopharmaceuticals have the potential to cause fetal harm. Therefore, Neuraceq should only be used in pregnant women if the potential benefit justifies the potential risk to the fetus. For nursing mothers, it is recommended to temporarily interrupt breastfeeding for 24 hours after administration, during which time breast milk should be pumped and discarded to minimize radiation exposure to the infant.[2]
• Pediatric Use: The safety and effectiveness of Neuraceq have not been established in pediatric patients, and it is not indicated for this population.[32]
• Geriatric Use: Clinical studies included a large number of elderly subjects, and no overall differences in safety or effectiveness were observed between subjects aged 65 and older and younger adult subjects.[32]

8.3 Radiation Dosimetry

Radiation dosimetry involves calculating the absorbed radiation dose to various organs and tissues in the body, as well as the total body effective dose. These calculations are based on biodistribution studies that track the tracer's movement and retention throughout the body over time.

• Effective Dose: The total whole-body effective dose resulting from a standard 300 MBq (8.1 mCi) administration of Neuraceq is estimated to be 5.8 mSv.[43] This level of radiation exposure is comparable to other commonly used ¹⁸F-labeled PET diagnostic agents, such as ¹⁸F-FDG, and is similar to the annual background radiation exposure in many parts of the world.[19] An earlier dosimetry study calculated a slightly lower effective dose of 4.4 mSv.[44] It is important to note that if the PET scan is performed on a hybrid PET/CT scanner, the patient will receive an additional radiation dose from the CT component, which varies depending on the CT acquisition parameters.
• Critical Organs: The organs that receive the highest absorbed radiation doses are those involved in the tracer's metabolism and excretion pathway. The dosimetry data directly reflects the hepatobiliary clearance of Florbetaben F-18. As the tracer and its radioactive metabolites are processed by the liver and concentrated in the gallbladder before being excreted into the intestines, these organs receive the highest radiation doses. The gallbladder wall is the critical organ, receiving the highest dose, followed by the urinary bladder wall, the upper large intestine wall, and the liver.[19]

Table 4: Estimated Radiation Absorbed Doses in Adult Patients Following Intravenous Administration of Neuraceq®

Organ/Tissue	Mean Absorbed Radiation Dose per Unit Administered Activity
Adrenals	13
Brain	13
Breasts	7
Gallbladder Wall	137
Heart Wall	14
Kidneys	24
Liver	39
Lower Large Intestine-Wall	35
Lungs	15
Muscle	10
Osteogenic Cells	15
Ovaries	16
Pancreas	14
Red Marrow	12
Skin	7
Small Intestine	31
Spleen	10
Stomach Wall	12
Testes	9
Thymus	9
Thyroid	8
Upper Large Intestine-Wall	38
Urinary Bladder Wall	70
Uterus	16
Total Body	11
Effective Dose (µSv/MBq)	19
Data sourced from.43 The whole-body effective dose from a 300 MBq administration is 5.8 mSv (	19μSv/MBq×300MBq).

---

Section 9: Comparative Analysis and Clinical Context

Florbetaben F-18 is one of three widely available ¹⁸F-labeled PET radiotracers for amyloid imaging. To fully appreciate its clinical role, it is necessary to compare it with its counterparts: florbetapir F-18 (Amyvid®) and flutemetamol F-18 (Vizamyl®). This section provides a comparative analysis of their chemical origins, imaging protocols, and diagnostic performance characteristics.

9.1 Chemical Origins and Structural Classes

The three tracers, while serving the same purpose, originate from different chemical scaffolds, which influences their intrinsic properties.

• Florbetaben F-18 (Neuraceq®): As previously described, this tracer is a stilbene derivative. Its chemical structure is related to Congo red, one of the earliest histological stains used to identify amyloid plaques in post-mortem tissue.[1]
• Florbetapir F-18 (Amyvid®): This tracer is a styrylpyridine derivative.[47] Its development was aimed at optimizing properties like BBB penetration and clearance kinetics.
• Flutemetamol F-18 (Vizamyl®): This tracer is a benzothiazole derivative. Its structure is closely related to Thioflavin T, another classic amyloid-binding dye, and it is a fluorinated analogue of the pioneering amyloid PET tracer, ¹¹C-Pittsburgh Compound-B (PiB).[46]

These fundamental structural differences can lead to variations in lipophilicity, plasma protein binding, metabolism, and the degree of non-specific binding to other brain structures, particularly white matter.

9.2 Comparison of Imaging Protocols

One of the most significant areas of practical difference among the tracers lies in their recommended clinical imaging protocols. These differences in timing have direct consequences for workflow, patient scheduling, and operational efficiency in a PET imaging center.[35]

• Neuraceq® (florbetaben): This tracer features the widest and most flexible uptake window, with image acquisition recommended between 45 and 130 minutes post-injection. The scan duration is 15 to 20 minutes. This flexibility can be a major advantage in managing the unpredictable delays of a clinical setting.
• Amyvid® (florbetapir): This tracer has the shortest overall procedure time. The uptake period is 30 to 50 minutes, and the scan itself is only 10 minutes long. This efficiency can allow an imaging center to maximize patient throughput.
• Vizamyl™ (flutemetamol): This tracer requires the longest uptake period, with scanning recommended between 60 and 120 minutes post-injection. The scan duration is 10 to 20 minutes.

The choice between these agents in a clinical setting may be influenced as much by these logistical factors as by their imaging characteristics. A center prioritizing maximum patient volume might favor florbetapir, while a center that requires greater flexibility to accommodate a complex schedule might prefer florbetaben.

9.3 Diagnostic Performance and Imaging Characteristics

From a clinical diagnostic standpoint, all three tracers are considered highly effective and largely interchangeable for their primary approved indication.

• Overall Accuracy: Rigorous PET-to-autopsy validation studies have been conducted for all three agents. These studies have consistently demonstrated high diagnostic performance, with reported sensitivity values in the range of 88% to 98% and specificity values from 80% to 95% for the visual detection of moderate to frequent neuritic plaques.[48] For the purpose of a binary clinical assessment (amyloid-positive vs. amyloid-negative), they are regarded as clinically equivalent.
• Head-to-Head Comparisons: While broadly equivalent, direct head-to-head comparison studies have revealed some subtle differences. A study directly comparing florbetaben (FBB) and flutemetamol (FMM) in the same subjects found an excellent linear correlation (R2=0.97) for tracer uptake in the cortex, confirming their comparability for assessing the primary regions of interest in AD.[49]
• Regional Differences and Non-Specific Binding: The same study, however, noted some nuanced distinctions. Flutemetamol appeared to provide a stronger signal in the striatum, showing a higher SUVR ratio and a larger effect size for distinguishing between amyloid-positive and -negative groups in this region.[49] Striatal amyloid deposition is an area of active research, potentially related to later stages of disease or specific clinical phenotypes. Therefore, for research focused on the striatum, flutemetamol might offer an advantage. Conversely, the study noted that florbetaben exhibited significantly higher non-specific binding in white matter compared to flutemetamol.[46] High white matter signal can sometimes reduce the visual contrast with adjacent gray matter, potentially making scan interpretation more challenging, especially for less experienced readers. While all ¹⁸F-tracers show more white matter binding than ¹¹C-PiB, the degree of this off-target binding varies among them, representing a key point of differentiation.

Table 5: Comparative Profile of FDA-Approved ¹⁸F-Amyloid PET Tracers

Feature	Florbetaben F-18 (Neuraceq®)	Florbetapir F-18 (Amyvid®)	Flutemetamol F-18 (Vizamyl®)
Chemical Class	Stilbene Derivative (Congo Red-like)	Styrylpyridine Derivative	Benzothiazole Derivative (Thioflavin T-like)
Uptake Window	45 - 130 minutes	30 - 50 minutes	60 - 120 minutes
Scan Duration	15 - 20 minutes	10 minutes	10 - 20 minutes
Reference Region	Whole Cerebellum	Whole Cerebellum	Pons
Key Characteristics	- High diagnostic accuracy - Widest, most flexible imaging window - Higher non-specific white matter binding	- High diagnostic accuracy - Shortest overall procedure time	- High diagnostic accuracy - Structurally similar to ¹¹C-PiB - Potentially superior striatal signal
Data sourced from.35

---

Section 10: Conclusion and Future Horizons

This final section synthesizes the key findings of this report, summarizing the established role of Florbetaben F-18 in the contemporary management of cognitive impairment, and explores its emerging applications and future trajectory.

10.1 Summary of Key Findings

Florbetaben F-18, marketed as Neuraceq®, is a robust and extensively validated radiopharmaceutical for the in-vivo visualization and estimation of cerebral β-amyloid neuritic plaque density. Its development and approval marked a significant advancement in the diagnosis of Alzheimer's disease, enabling a shift from a purely clinical, symptom-based diagnosis towards one grounded in the underlying biology of the disease.

The diagnostic efficacy of Florbetaben F-18 is unequivocally supported by pivotal Phase 3 clinical trial data, which demonstrated high sensitivity (98.2%) and specificity (92.3%) when compared directly against the definitive gold standard of post-mortem neuropathological examination. A key clinical strength is its high negative predictive value (96.0%), which allows clinicians to rule out AD pathology with a high degree of confidence in patients with cognitive impairment, thereby guiding further diagnostic workup towards other potential causes.

The agent possesses a favorable pharmacokinetic profile optimized for PET imaging, characterized by rapid brain uptake and efficient clearance of non-brain-penetrant metabolites, which creates a wide and flexible imaging window. Furthermore, its safety profile is excellent, with adverse events being rare, mild, and largely confined to transient injection site reactions.

The evolution of the Alzheimer's disease treatment landscape has profoundly elevated the clinical importance of Florbetaben F-18. The recent expansion of its FDA indication to include the selection of patients for amyloid-directed therapies has solidified its role as an indispensable companion diagnostic. It is no longer just a tool for diagnostic clarification but a gateway to accessing a new class of disease-modifying treatments.

10.2 Emerging Applications: Cardiac Amyloidosis

The utility of Florbetaben F-18 is not confined to the brain. The fundamental mechanism of binding to the β-sheet structure of amyloid fibrils is applicable to amyloid diseases affecting other parts of the body. There is a growing body of evidence demonstrating that Florbetaben F-18 can effectively image amyloid deposits in the heart.

This has led to a major development effort to expand its use into cardiology. Ongoing Phase 3 clinical trials are formally evaluating its diagnostic efficacy for cardiac amyloidosis, a life-threatening condition caused by the deposition of either light-chain (AL) or transthyretin (ATTR) amyloid proteins in the myocardium.[33] In recognition of the significant unmet medical need for non-invasive diagnostic tools for these rare diseases, Florbetaben F-18 has already received Orphan Drug Designation from both the FDA and EMA for this indication.[33] Successful completion of these trials could establish Florbetaben F-18 as a first-line, non-invasive imaging agent for the diagnosis and management of cardiac amyloidosis.

10.3 Future Outlook

The future for Florbetaben F-18 and amyloid PET imaging is dynamic and expanding. As new amyloid-targeting therapies for Alzheimer's disease receive approval and enter clinical practice, the demand for accurate and accessible amyloid PET scanning is expected to increase substantially. Florbetaben F-18 is well-positioned to meet this demand.

The field is also moving towards greater reliance on quantitative analysis. While visual interpretation remains the clinical standard, the use of quantitative metrics like SUVR will likely become more integrated into clinical reports. This will provide more objective measures of amyloid burden, which will be critical for monitoring disease progression and assessing the magnitude of plaque removal in response to therapy.

The potential expansion into cardiology highlights the platform potential of this technology. The principle of targeting the common structural motif of amyloid fibrils is not limited to one protein or one organ. This suggests that Florbetaben F-18 could be investigated for its utility in other forms of systemic amyloidosis affecting organs such as the kidneys or peripheral nerves. In essence, Florbetaben F-18 stands as a prime example of a molecular imaging agent that is not only central to the current paradigm of neurodegenerative disease diagnosis but also poised to expand its impact across multiple fields of medicine.

Works cited

1. Florbetaben (18F) | C21H26FNO3 | CID 11501341 - PubChem, accessed August 25, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Florbetaben-F-18
2. Florbetaben F-18 | C21H26FNO3 | CID 11501341 - PubChem, accessed August 25, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Florbetaben%20F%2018
3. Florbetaben (18F) - Wikipedia, accessed August 25, 2025, https://en.wikipedia.org/wiki/Florbetaben_(18F)
4. Neuraceq 300 MBq/mL solution for injection - SUMMARY OF PRODUCT CHARACTERISTICS, accessed August 25, 2025, https://neuraceq.com/wp-content/uploads/Neuraceq-Summary-of-Product-Characteristics-Ireland.pdf
5. florbetaben | Ligand page - IUPHAR/BPS Guide to PHARMACOLOGY, accessed August 25, 2025, https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7769
6. FLORBETABEN F-18 - Inxight Drugs, accessed August 25, 2025, https://drugs.ncats.io/drug/TLA7312TOI
7. Neuraceq (Florbetaben F 18 Injection): Side Effects, Uses, Dosage, Interactions, Warnings, accessed August 25, 2025, https://www.rxlist.com/neuraceq-drug.htm
8. Ethnic comparison of pharmacokinetics of 18F-florbetaben, a PET tracer for beta-amyloid imaging, in healthy Caucasian and Japanese subjects - PMC, accessed August 25, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4244559/
9. florbetaben F18 - Drug Central, accessed August 25, 2025, https://drugcentral.org/drugcard/4818
10. What is the mechanism of Florbetaben F-18? - Patsnap Synapse, accessed August 25, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-florbetaben-f-18
11. Reference ID: 3473704 - accessdata.fda.gov, accessed August 25, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204677s000lbl.pdf
12. Brain Imaging for Alzheimer's Disease Clinical Trials (Chapter 33), accessed August 25, 2025, https://www.cambridge.org/core/books/alzheimers-disease-drug-development/brain-imaging-for-alzheimers-disease-clinical-trials/1DB8AA382E789EAB91D4EDEB0FA8B63E
13. Florbetapir F-18: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed August 25, 2025, https://go.drugbank.com/drugs/DB09149
14. Florbetaben F-18: Uses, Interactions, Mechanism of Action ..., accessed August 25, 2025, https://go.drugbank.com/drugs/DB09148
15. NEURACEQ® (florbetaben F 18 injection), for intravenous use - accessdata.fda.gov, accessed August 25, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/204677s024s034lbl.pdf
16. Neuraceq® Amyloid Alzheimers PET Scan | Life Molecular Imaging, accessed August 25, 2025, https://neuraceq.com/hcp/neuraceq-scan/
17. HIGHLIGHTS OF PRESCRIBING INFORMATION These ... - Neuraceq, accessed August 25, 2025, https://neuraceq.com/wp-content/uploads/PRESCRIBING-INFORMATION.pdf
18. Beta-amyloid imaging with florbetaben - PMC - PubMed Central, accessed August 25, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4339690/
19. 204677Orig1s000 - accessdata.fda.gov, accessed August 25, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204677Orig1s000ClinPharmR.pdf
20. Ethnic comparison of pharmacokinetics of (18)F-florbetaben, a PET tracer for beta-amyloid imaging, in healthy Caucasian and Japanese subjects - PubMed, accessed August 25, 2025, https://pubmed.ncbi.nlm.nih.gov/25143073/
21. Ethnic comparison of pharmacokinetics of 18F-florbetaben, a PET ..., accessed August 25, 2025, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4244559/
22. Piramal Imaging Announces Publication of Phase III Neuraceq ..., accessed August 25, 2025, https://www.prnewswire.com/news-releases/piramal-imaging-announces-publication-of-phase-iii-neuraceq-florbetaben-f18-pet-imaging-data-in-alzheimers--dementia-300135164.html
23. Impact of Training Method on the Robustness of the Visual ..., accessed August 25, 2025, https://jnm.snmjournals.org/content/57/6/900
24. Alzheimer Disease | Study 14595 | Bayer - Clinical Trials Explorer, accessed August 25, 2025, https://clinicaltrials.bayer.com/study/14595
25. Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: A multicenter study - PMC, accessed August 25, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3468774/
26. Alzheimer's Disease Neuro-Imaging III (ADNI3) Study, accessed August 25, 2025, https://adni.loni.usc.edu/wp-content/uploads/2012/10/ADNI3_PET-Tech-Manual_V2.0_20161206.pdf
27. Overview of Alzheimer's Disease Neuroimaging Initiative and future clinical trials - PMC, accessed August 25, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11775462
28. Neuraceq | European Medicines Agency (EMA), accessed August 25, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/neuraceq
29. Piramal Imaging announces EU approval of NeuraCeq - NeuroNews International, accessed August 25, 2025, https://neuronewsinternational.com/piramal-imaging-announces-eu-approval-of-neuraceq/
30. Neuraceq (florbetaben F18) FDA Approval History - Drugs.com, accessed August 25, 2025, https://www.drugs.com/history/neuraceq.html
31. FDA Approves Piramal Imaging's NeuraceqTM (florbetaben F18 injection) for PET Imaging of Beta-Amyloid Neuritic Plaques in the Brain, accessed August 25, 2025, https://wmis.org/fda-approves-piramal-imagings-neuraceqtm-florbetaben-f18-injection-for-pet-imaging-of-beta-amyloid-neuritic-plaques-in-the-brain/
32. Safety Information Neuraceq® Florbetaben F-18 | Life Molecular Imaging, accessed August 25, 2025, https://neuraceq.com/safety-information/
33. European Commission Grants Orphan Drug Designation to Florbetaben (18F) for Diagnosis of ATTR Amyloidosis - Life Molecular Imaging, accessed August 25, 2025, https://life-mi.com/european-commission-grants-orphan-drug-designation-to-florbetaben-18f-for-diagnosis-of-attr-amyloidosis/
34. Life Molecular Imaging Announces Start of Phase 3 Study with [18F]Florbetaben in Cardiac Amyloid Light Chain (AL) Amyloidosis, accessed August 25, 2025, https://life-mi.com/life-molecular-imaging-announces-start-of-phase-3-study-with-18fflorbetaben-in-cardiac-amyloid-light-chain-al-amyloidosis/
35. Dosing & Procedure | Amyvid® (Florbetapir F 18 Injection) - Eli Lilly, accessed August 25, 2025, https://amyvid.lilly.com/hcp/dosing-procedure
36. Neuraceq-Imaging-protocol_Version-4-2.pdf, accessed August 25, 2025, https://neuraceq.com/wp-content/uploads/2022/04/Neuraceq-Imaging-protocol_Version-4-2.pdf
37. MESA-MIND Manual of Operations: Florbetaben PET - The Multi-Ethnic Study of Atherosclerosis, accessed August 25, 2025, https://internal.mesa-nhlbi.org/sites/default/files/2023-08/2023_0828_MESApetMOP_FBB.pdf
38. Visual interpretation of 18 F-florbetaben brain PET/CT for evaluation of abnormal amyloid plaque deposition is corroborated and enhanced with a quantitative analysis software package. - Journal of Nuclear Medicine, accessed August 25, 2025, https://jnm.snmjournals.org/content/62/supplement_1/1075
39. Quantification of amyloid PET for future clinical use: a state-of-the-art review - PMC, accessed August 25, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9308604/
40. Life Molecular Imaging and SOFIE announce Neuraceq® availability in Albany, NY, accessed August 25, 2025, https://life-mi.com/life-molecular-imaging-and-sofie-announce-neuraceq-availability-in-albany-ny/
41. Florbetaben f 18 (intravenous route) - Side effects & uses - Mayo Clinic, accessed August 25, 2025, https://www.mayoclinic.org/drugs-supplements/florbetaben-f-18-intravenous-route/description/drg-20312506
42. Life Molecular Imaging announces presentation of new scientific data at the Alzheimer's Association International Conference - Neuraceq® Florbetaben F-18 Injection, accessed August 25, 2025, https://neuraceq.com/2022/08/16/life-molecular-imaging-announces-presentation-of-new-scientific-data-at-the-alzheimers-association-international-conference/
43. Neuraceq Dosage Guide - Drugs.com, accessed August 25, 2025, https://www.drugs.com/dosage/neuraceq.html
44. Radiation Dosimetry of β-Amyloid Tracers 11 C-PiB and 18 F-BAY94-9172, accessed August 25, 2025, https://jnm.snmjournals.org/content/50/2/309
45. Radiation exposure by [F18]Florbetaben, a new PET tracer for detection of cerebral β-amyloid in Caucasian and Asian healthy volunteers | Journal of Nuclear Medicine, accessed August 25, 2025, https://jnm.snmjournals.org/content/51/supplement_2/1448
46. Head-to-Head Comparison of 18F-Florbetaben and 18F-Flutemetamol in the Cortical and Striatal Regions - PMC, accessed August 25, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9711935/
47. Structures of AZD4694, PiB, flutemetamol, and florbetapir. - ResearchGate, accessed August 25, 2025, https://www.researchgate.net/figure/Structures-of-AZD4694-PiB-flutemetamol-and-florbetapir_fig6_261138714
48. Updated Appropriate Use Criteria for Amyloid and Tau PET: A ..., accessed August 25, 2025, https://jnm.snmjournals.org/content/early/2025/01/07/jnumed.124.268756
49. (PDF) Head-to-Head Comparison of F-Florbetaben and F-Flutemetamol in the Cortical and Striatal Regions - ResearchGate, accessed August 25, 2025, https://www.researchgate.net/publication/341659005_Head-to-Head_Comparison_of_F-Florbetaben_and_F-Flutemetamol_in_the_Cortical_and_Striatal_Regions
50. Head-to-Head Comparison of 18F-Florbetaben and 18F-Flutemetamol in the Cortical and Striatal Regions - PubMed, accessed August 25, 2025, https://pubmed.ncbi.nlm.nih.gov/32474468/
51. Head-to-Head Comparison of 18F-Florbetaben and 18F ..., accessed August 25, 2025, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9711935/
52. Study Details | Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL Amyloidosis, accessed August 25, 2025, https://www.clinicaltrials.gov/study/NCT05184088?term=FLORBETABEN%20F-18&rank=6